Genz-123346 (free base)

Genz-123346 free base is an orally available inhibitor of glucosylceramide synthase. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 of 14 nM[1].

Product Specifications

CAS Number

[491833-30-8]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Cancer-Kinase/protease

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Genz-123346-free-base.html

Purity

99.57

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CCCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C(OCCO3)C3=C2)O)=O

Molecular Formula

C24H38N2O4

Molecular Weight

418.57

Precautions

H315, H319, H335

References & Citations

[1]Zhao H, et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes. 2007 May;56 (5) :1210-8.|[2]Chai L, et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int J Oncol. 2011 Mar;38 (3) :701-11.|[3]Shen W, et al. Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. J Neurochem. 2014 Jun;129 (5) :884-94|[4]Natoli TA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010 Jul;16 (7) :788-92.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Faculty of Life Sciences, University College London. 2019 Oct.|Front Pharmacol. 2024 Oct 1:15:1409625.|Hepatol Commun. 2025 Sep 5;9 (9) :e0793.|Int Immunopharmacol. 2025 Sep 13:165:115532.|Nat Cell Biol. 2025 Mar;27 (3) :449-463.|PeerJ. 2021 Sep 14:9:e12138.|Am J Respir Crit Care Med. 2019 Nov 1;200 (9) :1113-1125.